Health · Hardware · Enterprise
Pearl Diagnostics, Inc.
Pearl Diagnostics is a Baltimore-based in vitro diagnostics company spun out of Johns Hopkins University that develops non-invasive urine tests to detect life-threatening lung infections. Its proprietary Smart Antibody technology identifies circulating microbial extracellular vesicles, and its lead product, the MycoMEIA Aspergillus Assay, became the first urine-based test to win FDA 510(k) clearance for aiding diagnosis of invasive aspergillosis. The company raised an $11.2M Series A in March 2026 to commercialize in the US and expand across Europe.